АТЕРОСКЛЕРОЗДОН КЕЛИП ЧЫККАН ЖҮРӨК-КАН ТАМЫР ООРУЛАРЫН ДАРЫЛООДО АЙКАЛЫШКАН ЛИПИДДИ ТӨМӨНДӨТҮҮЧҮ ТЕРАПИЯНЫН (РОЗУВАСТАТИН/ЭЗЕТИМИБ) ОРДУ
DOI:
https://doi.org/10.54890/1694-8882-2025-1-45Аннотация
Жүрөк-кан тамыр оорулары дүйнө жүзү боюнча өлүмдүн негизги себеби болуп саналат. Мындан тышкары, алардан өлүм жыл сайын көбөйүп, негизги үлүшү атеросклероздук оорусу менен шартталган. Бүткүл дүйнө жүзү боюнча атеросклероздук оорусу жогорку таралышы бейтаптарда бир катар коркунуч факторлорунун болушу менен шартталган. Жогорку кан басымы, кант диабети, тамеки чегүү, физикалык кыймылсыздык, семирүү сыяктуу белгилүү факторлордон тышкары, гиперлипидемия атеросклероздук оорусу өнүгүшүндө маанилүү роль ойнойт. Ошентип, тыгыздыгы төмөн липопротеиндер холестеринин деңгээли жогору болгон адамдарда нормалдуу деңгээли бар адамдарга караганда атеросклероз оорусунун өнүгүү коркунучу 2 эсе жогору. Ошондуктан, атеросклероз оорусу менен күрөшүүдө алдын алуу чаралары катары, ашыкча салмак, тамеки чегүү, алкоголдук ичимдиктерди токтотуу, физикалык кыймылсыздык, гипергликемия, жогорку кан басымы, сыяктуу факторлор менен гана эмес, ошондой эле гиперхолестеринемияны контролдоо зарыл. Статиндер атеросклероз оорусу жана аны менен байланышкан атеросклероз оорусу өнүгүшүн алдын алууга багытталган дары катары, негизги жана экинчилик алдын алууда колдонулган эң көп изилденген дарылар болуп саналат. Бирок, статиндерди колдонуп жатканда, бейтаптардын болжол менен 1/3 холестерин максаттуу деңгээлге жетет. Мындан тышкары, кээде (өтө сейрек болсо да) терс таасирлери, анын ичинде миопатия жана рабдомиолиз, кант диабетинин жаңы учурлары пайда болушу мүмкүн. Холестерин максаттуу деңгээлине жетүү жыштыгын жогорулатуу жана терс таасирлердин пайда болуу коркунучун азайтуу үчүн синергетикалык аракет механизми бар липидди төмөндөтүүчү дарыларды айкалыштыруу жана аларды 1 таблетканын ичинде колдонуу сунушталат. Мындай айкалышы - ичегидеги холестеролду кайра сиңирүүгө тоскоол болгон статин + эзетимиб. Эң чоң гиполипидемиялык таасири бар Розувастатин, статин катары сунушталат. Розувастатин + эзетимибдин айкалышы статиндик монотерапияга караганда төмөн липопротеиндер холестеролунун төмөндөтүү жана терс таасирлердин өнүгүшүн азайтуу жагынан артыкчылыкты көрсөттү.
Ключові слова:
атеросклероздук оорусу, холестерин, төмөн липопротеиндер холестеринин, гиперхолестеринемия, статин, эзетимибПосилання
1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
2. World Health Organization. Cardiovascular diseases (CVDs). 2022; Accessed February 29, 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/ cardiovascular-diseases-(cvds)
3. Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022;10(3):e369-e379. https://doi.org/10.1016/S2214-109X(21)00551-9
4. World Health Organization. Cardiovascular Diseases Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
5. Michaeli DT, Michaeli JC, Albers S, Tobias Boch T, Michaeli T. Established and Emerging Lipid‑Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023;23:477–495. https://doi.org/10.1007/ s40256-023-00594-5
6. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al.. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5
7. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297. https://doi.org/10.1001/jama.2016.13985
8. Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79:1802–1813. https://doi.org/10.1016/j.jacc.2022.02.048
9. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014
10. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101
11. Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022. 43(34):3213-3223 https://doi.org/10.1093/eurheartj/ehac015
12. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571. https://doi.org/10.1016/S0140-6736(12)61190-8
13. Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131-49. https://doi.org/10.1002/pds.4020
14. Reith C, Preiss D, Blackwell L, Emberson J, Spata E, Davies K, et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306–319. https://doi.org/10.1016/ S2213-8587(24)00040
15. Kim YS, Han YE, Choi EA, You NY, Lee JW, You HS, et al. Statin use increased new-onset diabetes in hypercholesterolemic individuals: data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS). Prim Care Diabetes. 2020;14(3):246-253. https://doi.org/10.1016/ j.pcd.2019.08.005
16. Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci. 2020;21(13):4725. https://doi.org/10.3390/ijms21134725
17. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89. https://doi.org/10.1093/eurjpc/zwaa047
18. Talic S, Marquina C, Zomer E, Ofori-Asenso R, Petrova M, Vargas-Torres S, et al. Attainment of low-density lipoprotein cholesterol goals in statin treated patients: Real-world evidence from Australia. Curr Probl Cardiol. 2022;47(7):101068. https://doi.org/10.1016/j.cpcardiol.2021.101068
19. Klimchak AC, Patel MY, Iorga ŞR,Kulkarni N, Wong ND. Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. Am J Prev Cardiol. 2020;1:100010. https://doi.org/10.1016/j.ajpc.2020.100010
20. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19(2):221–30. https://doi.org/10.1177/1741826711400545
21. Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis. 2017;266:158-166. https://doi.org/10.1016/j.atherosclerosis. 2017.08.013
22. Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5):371–382. https://doi.org/10.1111/1755-5922.12213
23. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. The Lancet. 2022;400(10349):380–390. https://doi.org/10.1016/S0140-6736(22)00916-3
24. Lee SJ, Cha JJ, Choi WG, Lee WS, Jeong JO, Choi S, et al. Moderate-intensity statin with ezetimibe combination therapy vs high-intensity statin monotherapy in patients at very high risk of atherosclerotic cardiovascular disease: a post hoc analysis from the RACING randomized clinical trial. JAMA Cardiol. 2023;8(9):853–858. https://doi.org/10.1001/jamacardio. 2023.2222
25. Lee YJ, Cho JY, You SC, Lee YH, Yun KH, Cho YH, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur. Heart J. 2022;44(11):972–983. https://doi.org/10.1093/eurheartj/ehac709
26. Lee B, Hong SJ, Rha SW, Heo JH, Hur SH, Choi HH, et al. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: a post-hoc analysis of the RACING randomized trial. Atherosclerosis. 2023;386:117373. https://doi.org/10.1016/ j.atherosclerosis.2023.117373
27. Schiele F, Pérez de Isla L, Arca M, Vlachopoulos C. Is it Time for Single ‑Pill Combinations in Dyslipidemia? Am J Cardiovasc Drugs. 2022;22(3):239-249. https://doi.org/10.1007/s40256-021-00498-2
28. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. https://doi.org/10.1056/NEJMoa1410489
29. Deng CJ, Yan J, Zheng YY, Wu TT, Pan Y, Hou XG, et al. Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials. BMJ Open. 2023;13(11):e070827. https://doi.org/ 10.1136/bmjopen-2022-070827
30. Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101(11):1606-1613. https://doi.org/10.1016/ j.amjcard.2008.01.041
31. Kelly FA, de Moraes FCA, Lôbo AOM, Siebel VM, Leite M, de Almeida AM, et al. Safety and Efficacy of Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis. J Clin Lipidol. 2024 Aug 14:S1933-2874(24)00230-7. https://doi.org/10.1016/j.jacl.2024.07.013
32. Grant JK, Orringer CE. High-intensity statins vs. moderate-intensity statin-ezetimibe combination therapy: A patient centered approach. J Clin Lipidol. 2024 Jul 27:S1933-2874(24)00216-2. https://doi.org/10.1016/j.jacl.2024.07.013
33. Lin Wu FL, Wang J, Ho W, Chou CH, Wu YJ, Choo DW, et al. Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: a 6-year population-based cohort study. Int J Cardiol. 2017;233:43–51. https://doi.org/10.1016/j.ijcard.2017.02.006
34. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-427. https://doi.org/10.2147/ VHRM.S33664
35. Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012 Aug;223(2):251–261. https://doi.org/10.1016/j.atherosclerosis. 2012.02.016
36. Nusbaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G. Ezetimibe-statin combination therapy. Efficacy and safety as compared with statin monotherapy – a systematic review. Dtsch Arztebl Int. 2016;113(26):445–453. https://doi.org/10.3238/arztebl.2016.0445
37. Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. Drug Des Devel Ther. 2022;16:2177-2186. https://doi.org/10.2147/DDDT.S332352
38. Francis AA, Pierce GN. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol. 2011l;16(3):77-86.
39. Dadzie SK, Tabowei G, Kaur M, Ahmed S, Thakur A, Khreis K, et al. A Comparison of Rosuvastatin Monotherapy and Rosuvastatin Plus Ezetimibe Combination Therapy in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. 2024 Cureus. 2024. Jun 2;16(6):e61526. https://doi.org/10.7759/ cureus.61526
40. Strilchuk L, Tocci G, Fogacci F, Cicero AFG. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother. 2020;21(5):531-539. https://doi.org/10.1080/14656566.2020.1714028
41. Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014;232(1):86–93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022
42. Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, et al. The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes mellitus: a randomized, multicenter, open, parallel, phase 4 study.Diabetes Metab J 2023;47(6):818-25. https://doi.org/10.4093/dmj.2023.0171
43. Han JH, Joung KH, Lee JC, Kim OS, Choung S, Kim JM, et al. Comparative efficacy of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus. Diabetes Metab J. 2024;48(1):112-121. https://doi.org/10.4093/ dmj.2022.0402
44. Wan S, Ding Y, Ji X, Meng R. The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. Aging Dis. 2021;12(8):1857-1871. https://doi.org/ 10.14336/AD.2021.0412
45. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673–680. https://doi.org/10.1016/j.amjcard.2006.10.022
46. Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong rosuvastatin & ezetimibe for hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226–241.e4. https://doi.org/10.1016/j.clinthera. 2017.12.018
47. Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROSE (Multicenter randomized study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5):371–382. https://doi.org/10.1111/1755-5922.12213
48. Kouvelos G, Arnaoutoglou E, Matsagkas M, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013;18(1):5-12. https://doi.org/10.1177/1074248412445506
49. Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2019;43(5):582-589. https://doi.org/10.4093/dmj.2018.0124
50. Djousse L, Benkeser D, Arnold A, Kizer JR, Zieman SJ, Lemaitre RN, et al. Plasma free fatty acids and risk of heart failure: the cardiovascular health study. Circ Heart Fail. 2013;6(5):964–969. https://doi.org/10.1161/CIRCHEARTFAILURE. 113.000521
51. Rea F, Savaré L, Corrao G, Mancia G. Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe. Adv Ther. 2021;38:5270–5285. https://doi.org/10.1007/s12325-021-01892-7
52. Perez de Isla L, Liberopoulos E, Dovizio M, Veronesi C, Degli Esposti L, Zambon A. Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/ Ezetimibe: Findings from a Real-World Analysis in Italy. Adv Ther. 2024;41(8):3407-3418. https://doi.org/10.1007/s12325-024-02916-8
53. Zambon A, Liberopoulos E, Dovizio M, Veronesi C, Degli Esposti L, Pérez de Isla L. A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin/ezetimibe as single-pill combination vs. free combination in Italy. Eur Heart J Open. 2024;4(5):oeae074. https://doi.org/ 10.1093/ehjopen/oeae074
54. Wilke T, Weisser B, Predel HG, Schmieder RE, Wassmann S, Gillessen A, et al. Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany. J Comp Eff Res. 2022;11(6):411–422. https://doi.org/10.2217/cer-2021-0197
55. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
56. Natale F, Molinari R, Franzese R, Mollo N, Cimmino G. Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken? Future Pharmacol. 2023;3(2):392–406. https://doi.org/10.3390/futurepharmacol3020024
##submission.downloads##
Жарыяланганы
Як цитувати
Номер
Розділ
